Real World Study on Prevalence, Treatment and Economic Burden of Myasthenia Gravis in Italy

Medientyp: E-Book

Titel: Real World Study on Prevalence, Treatment and Economic Burden of Myasthenia Gravis in Italy

Beteiligte: Antonini, Giovanni [Verfasser:in]; Habetswallner, Francesco [Verfasser:in]; Inghilleri, Maurizio [Verfasser:in]; Mantegazza, Renato [Verfasser:in]; Rodolico, Carmelo [Verfasser:in]; Saccà, Francesco [Verfasser:in]; Sgarzi, Manlio [Verfasser:in]; deRuyck, Femke [Verfasser:in]; Paci, Sandra [Verfasser:in]; Phillips, Glenn [Verfasser:in]; Crippa, Laura [Verfasser:in]; Veronesi, Chiara [Verfasser:in]; Perrone, Valentina [Verfasser:in]; Degli Esposti, Luca [Verfasser:in]

Erschienen: [S.l.]: SSRN, 2023

Umfang: 1 Online-Ressource (21 p)

Sprache: Englisch

DOI: 10.2139/ssrn.4312649

Identifikator:

Schlagwörter: myasthenia gravis ; Pyridostigmine ; Real word evidence ; Epidemiology ; Healthcare resource consumption ; administrative databases

Entstehung:

Anmerkungen:

Beschreibung: This real-world analysis aims to gain insights on the epidemiology, management, and economic burden of myasthenia gravis in settings of clinical practice. The analysis used administrative databases covering around 12 million subjects across Italy and included all adult patients with hospitalization discharge diagnosis or active exemption code for myasthenia gravis or with ≥1 pyridostigmine prescription between 01/2011-12/2018. Prevalence of myasthenia gravis for 2018 ranged between 13.5-29.3 patients per 100,000 health-assisted subjects (depending on the criteria applied). Data projected to Italian population estimated 8,190-17,728 alive patients in 2018. The analyses involved 4,397 patients with myasthenia gravis (mean age 61.7 years, 46.6% male); a sustained pyridostigmine use has been detected (84.0% to 46.8% from 1st to 3rd year of follow-up), followed by corticosteroids (54.5% to 44.6% from 1st to 3rd year of follow-up) and non-steroidal immunosuppressants (16% over follow-up). Total direct healthcare costs for myasthenia gravis patients were 4-times more than those of the general population (€3,771 and €869, respectively), and up to 9-fold more if considering patients with exacerbation (€7,827). Findings from the analysis showed the epidemiologic burden of myasthenia gravis and the complexity of the therapeutic management for patients affected, with consistent use of treatments and an elevated resource consumption

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: